Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL-Reference-Cited by-同舟云学术

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Published:2022-11-17 Issue:20 Volume:140 Page:2175-2179
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rejeski Kai¹²³^ORCID,Wu Zhijie⁴^ORCID,Blumenberg Viktoria¹²³^ORCID,Kunz Wolfgang G.⁵^ORCID,Müller Susanna⁶,Kajigaya Sachiko⁴,Gao Shouguo⁴,Bücklein Veit L.¹²^ORCID,Frölich Lisa¹³,Schmidt Christian¹,von Bergwelt-Baildon Michael¹³,Feng Xingmin⁴,Young Neal S.⁴,Subklewe Marion¹²³^ORCID

Affiliation:

1. 1Department of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany

2. 2Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany

3. 3German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany

4. 4Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

5. 5Department of Radiology, University Hospital, LMU Munich, Munich, Germany

6. 6Department of Pathology, University Hospital, LMU Munich, Munich, Germany

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/140/20/2175/1982928/blood_bld-2022-017015-main.pdf

Reference25 articles.

1. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma;Locke;N Engl J Med,2022

2. Early and late hematologic toxicity following CD19 CAR-T cells;Fried;Bone Marrow Transplant,2019

3. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies;Jain;Blood Adv,2020

4. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy;Juluri;Blood Adv,2021

5. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma;Rejeski;Blood,2021

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management;The Lancet Haematology;2024-06

2. Mechanisms and management of CAR T toxicity;Frontiers in Oncology;2024-05-21

3. Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC);Bulletin du Cancer;2024-04

4. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study);Blood Advances;2024-03-26

5. Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies;International Journal of Molecular Sciences;2024-02-19